Cellectis S.A. (CLLS) stock

CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 20, 2026Score 3/30

$1.18−0.15 (-11.28%)

Close on Nov 13, 2026Market cap $118.40MP/E –Yield –

Cellectis statistics

80 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings: –
Last ex-dividend date: No dividends
Fundamentals through: Jun 30, 2026
Share price as of: Nov 13, 2026

Valuation ratiosIndustry

Market Cap: $118.40M; $272.32M
Enterprise Value: $82.81M; $146.23M
PS Ratio: 1.62; 3.66
PB Ratio: 2.88; 2.00
P/TBV Ratio: 2.96; 2.22

Enterprise valuationIndustry

EV / Sales: 1.14; 2.57

Share statisticsIndustry

Shares Outstanding: 100M; 58M
Shares Change (YoY): 10.7%; 10.8%
Float: 47M; 49M
Shares Held by Insiders: 53.4%; 11.7%
Shares Held by Institutions: 9.45%; 56.4%

Short sellingIndustry

Short Interest: 333,012; –
Short Interest Change: 3.87%; -0.80%
Days to Cover: 2.63; 5.15

Stock price statisticsIndustry

52-Week High: $5.45; –
52-Week Low: $0.88; –
20-Day Moving Average: $1.09; –
50-Day Moving Average: $1.45; –
200-Day Moving Average: $2.92; –
Average True Range (14): $0.14; –
Price Change (1 Week): 10.3%; -1.15%
Price Change (1 Month): 6.79%; -4.87%
Price Change (3 Months): -62.1%; -21.0%
Price Change (6 Months): -69.9%; -20.6%
Price Change (YTD): -75.6%; -23.6%
Price Change (1 Year): -67.7%; -22.4%
Price Change (3 Years): -53.9%; -29.5%
Price Change (5 Years): -88.8%; -77.9%
Price Change (10 Years): -93.8%; -65.4%
Average Volume (10 Days): 70,420; –
Average Volume (20 Days): 102,751; –
Average Volume (90 Days): 85,863; –
Relative Volume: 0.85; 0.70
Relative Strength Index (14): 47.4; 43.4
Volatility (1 Year): 90.5%; 80.1%
Beta (5 Years): 2.07; 1.07

MarginsIndustry

Gross Margin: 100.0%; 53.1%
Operating Margin: -45.3%; -38.7%
Pretax Margin: -93.2%; -11.6%
Profit Margin: -92.7%; -31.6%
EBITDA Margin: -17.8%; -27.7%
FCF Margin: -57.2%; -9.56%

Returns on capitalIndustry

Return on Equity (ROE): -97.8%; -49.9%
Return on Assets (ROA): -21.8%; -40.6%
Return on Invested Capital (ROIC): -122.2%; -32.9%
Return on Capital Employed (ROCE): -25.0%; -37.9%

Financial positionIndustry

Quick Ratio: 0.30; 2.39
Interest Coverage: -0.65; -6.35

GrowthIndustry

Revenue Growth (YoY): 75.8%; 6.82%
FCF Growth (YoY): -304.7%; 6.85%
Revenue Growth (3Y CAGR): 56.1%; 2.25%
Revenue Growth (5Y CAGR): 7.40%; 6.41%

EfficiencyIndustry

Asset Turnover: 0.23; 0.40
Revenue Per Employee: $318.56K; $429.29K
Profits Per Employee: -$295.17K; -$689.41K
Employee Count: 229; 74
WACC: 15.4%; 10.2%

Income statement (TTM)Industry

Revenue: $72.95M; $66.37M
Gross Profit: $72.95M; $120.78M
Operating Income: -$33.08M; -$21.37M
Pretax Income: -$68.02M; -$12.95M
Net Income: -$67.59M; -$22.35M
EBITDA: -$13.01M; -$17.21M
EPS (Diluted): -$0.67; -$0.76

Balance sheetIndustry

Cash & Short-Term Investments: $35.59M; $68.68M
Net Cash (Debt): $35.59M; $17.76M
Net Cash Per Share: $0.35; $0.80
Equity (Book Value): $41.07M; $53.89M
Book Value Per Share: $0.41; $1.50
Tangible Book Value: $39.95M; $27.13M

Cash flow (TTM)Industry

Operating Cash Flow: -$39.40M; -$12.38M
Capital Expenditures: -$2.36M; -$1.00M
Free Cash Flow: -$41.76M; -$18.21M
FCF Per Share: -$0.42; -$0.42

Dividends and yieldsIndustry

Earnings Yield: -57.1%; -21.8%
FCF Yield: -35.3%; -9.44%

Taxes and interestIndustry

Interest Expense: $51.06M; $2.90M
Income Tax: -$423.00K; $73.00K

Scores and fair valueIndustry

Altman Z-Score: 0.18; 0.23
Piotroski F-Score: 3; 4

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

Period	CLLS	S&P 500	Difference	CLLS per year	S&P 500 per year
1 month	+7.3%	-3.0%	+10.3 pts
3 months	-62.9%	-2.8%	−60.1 pts
Year to date	-75.6%	+11.5%	−87.1 pts
1 year	-66.9%	+13.5%	−80.4 pts
3 years	-53.2%	+77.7%	−130.9 pts	-22.3%	+21.1%
5 years	-88.8%	+72.6%	−161.4 pts	-35.5%	+11.5%
10 years	-93.8%	+308.2%	−402.0 pts	-24.3%	+15.1%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

0M CLLS shares were sold short on Oct 30, 2026, up 3.9% from the previous report. At recent volumes it would take 2.6 days to buy them back. Over the last 20 sessions, 35.8% of the volume reported to FINRA was short selling.

Settlement date	Shares short	Change	Avg. daily volume	Days to cover
Oct 30, 2026	333,012	+3.9%	126,736	2.6
Oct 15, 2026	320,614	-8.7%	82,709	3.9
Sep 30, 2026	351,327	-28.0%	152,427	2.3
Sep 15, 2026	488,061	+68.5%	207,376	2.4
Aug 31, 2026	289,689	-4.0%	16,586	17.5
Aug 14, 2026	301,671	+1.9%	21,274	14.2
Jul 31, 2026	295,914	+2.2%	13,431	22.0
Jul 15, 2026	289,618	-10.0%	17,239	16.8
Jun 30, 2026	321,876	-13.3%	36,330	8.9
Jun 15, 2026	371,270	+5.4%	58,892	6.3
May 29, 2026	352,107	+4.3%	37,853	9.3
May 15, 2026	337,444	-7.3%	22,053	15.3